CDK4/6

Oncology

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies worldwide.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.